Lipid Alterations in Glioma: A Systematic Review

Rashid, Khairunnisa Abdul; Ibrahim, Kamariah; Wong, Jeannie Hsiu Ding; Ramli, Norlisah

doi:10.3390/metabo12121280

Cited by 12 publications

(9 citation statements)

References 250 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fatty acyls such as hexadecanedioic acid and 3hydroxybutyric acid were also downregulated after surgery. The upregulation of sterol lipids including glycodeoxycholic acid, glycocholic acid, and taurocholic acid after surgery could be related, at least in part, to the dysregulated lipid metabolism in glioma [31]. The downregulation of riluzole, a benzothiazole with an organoheterocyclic compound super class, is not fully clear, as our patients were not on exogenous treatment with riluzole.…”

Section: Discussionmentioning

confidence: 87%

Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment

Aboud,

Liu,

Dahabiyeh

et al. 2023

Preprint

View full text Add to dashboard Cite

Introduction: This study aims to characterize changes in biogenic amines patterns in glioblasto-ma patients undergoing surgery and concurrent chemoradiation to illustrate how this class of metabolites changes during different stages of standard care treatment protocol. Methods: We examined 138 plasma specimens (before surgery, 2 days after surgical resection, before starting concurrent chemoradiation, immediately after chemoradiation, and after adju-vant chemotherapy treatment) from 36 patients with isocitrate dehydrogenase (IDH) wildtype glioblastoma. Untargeted GC-TOF mass spectrometry-based metabolomics of biogenic amines was used given its superiority for identifying and quantitating small metabolites; this yielded 340 structurally identified metabolites. Results: Comparing post-surgery to pre-surgery showed increased level of 12 metabolites: Gly-codeoxycholic acid (P=7.79E-05), Betonicine (P=9.23E-05), Glycocholic acid (P=3.18E-03), 3-Cysteinylaectaminophen (P=4.95E-03), S-Methyl-3-thioacetaminophen (P=5.77E-03), Tau-rocholic acid (P=9.97E-03), N-glycine (P=0.0013), p-acetamidophenyl.beta.-D-glucuronide (P=0.0048), 2-Hydroxy-5-sulfopyridine-3-carboxylic acid (P=0.0074), Acetaminophen sulfate (P=0.0095), 2-Amino-3-methoxybenzoic acid (P=0.02), and Dehydrofelodipine (P=0.024). There were 11 compounds that were downregulated, which included Mannitol (P=1.96E-19), Sorbitol (P=2.75E-019), Linoleic acid (P=1.51E-10), 1-Methylnicotinamide (P=1.78E-09), Nudifloramide (P=2.81E-08), Hexadecanedioic acid (P=5.49E-05), 3-Hydroxybutyric acid (P=0.0002), Riluzole (0.0036), Bupivacaine (P=0.0041), Lactitol (P=0.008), and 1-hydroxymidazolam.beta.-D-glucuronide (P=0.0414). After chemoradiation, significant de-crease was uncovered in Famotidine (P=0.0074), N-Isovalerylglycine (P=0.012), and 3-Methylcrotonylglycine (P=0.0131). While significant increase was detected in N-Methylisoleucine (P=0.0011), 4-Methyl-5-thiazoleethanol (P=0.042), and 6-Hydroxycaproic acid (P=0.049). Ensemble learning models, specifically random forest (RF) and AdaBoost (AB), accurately classified treatment phases with high accuracy (RF: 0.81 ± 0.04, AB: 0.78 ± 0.05). One significant insight gleamed from these models were that the metabolites Sorbitol and N-methylisoleucine were identified as important predictive features and confirmed by SHAP analysis. Conclusion: To our knowledge, this is the first study to describe plasma biogenic amines signa-tures during different treatment phases in patients with glioblastoma. A larger study is needed to confirm the results and the potential application of this algorithm for classification of treatment responses.

show abstract

Section: Discussionmentioning

confidence: 87%

Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment

Aboud,

Liu,

Dahabiyeh

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…24-1, 204-n6, 205-n3, PA-31:0 as a total lipid, ceramide, free fatty acid, and sphingomyelin lipid fractions. 66 – 70 The most common lipid changes in serum include diverse lipid species ranging from 140, 150, 180, 220, 240, 260, 280, 300, and 26.1 as lipid fractions. The most common lipid changes in plasma include diverse lipid species ranging from 160, 180, 240, 16.1 n-7, 201, 183 n-3, lpc-18.2, PE-18.1/202, SM-38.8 contained as a total lipid, free fatty acids lipid fractions.…”

Section: Resultsmentioning

confidence: 99%

“…The most common lipid changes in plasma include diverse lipid species ranging from 160, 180, 240, 16.1 n-7, 201, 183 n-3, lpc-18.2, PE-18.1/202, SM-38.8 contained as a total lipid, free fatty acids lipid fractions. 66 – 70 The most common lipid changes in erythrocytes include diverse lipid species ranging from 18:0, 20:0, 18:1 n-9, 24:1, and 20:4 n-6 containing total lipid fraction. 66 – 70 The most common lipid changes in adipose tissue include diverse lipid species ranging from 16:1 n-9, 20:1, 18:3 n-6, and 22:4 n-6 contained as a total lipid fraction.…”

Section: Resultsmentioning

confidence: 99%

“… 66 – 70 The most common lipid changes in erythrocytes include diverse lipid species ranging from 18:0, 20:0, 18:1 n-9, 24:1, and 20:4 n-6 containing total lipid fraction. 66 – 70 The most common lipid changes in adipose tissue include diverse lipid species ranging from 16:1 n-9, 20:1, 18:3 n-6, and 22:4 n-6 contained as a total lipid fraction. 66 – 70 …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Uncovering novel therapeutic targets in glucose, nucleotides and lipids metabolism during cancer and neurological diseases

Jovičić

2024

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

Background Cell metabolism functions without a stop in normal and pathological cells. Different metabolic changes occur in the disease. Cell metabolism influences biochemical and metabolic processes, signaling pathways, and gene regulation. Knowledge regarding disease metabolism is limited. Objective The review examines the cell metabolism of glucose, nucleotides, and lipids during homeostatic and pathological conditions of neurotoxicity, neuroimmunological disease, Parkinson’s disease, thymoma in myasthenia gravis, and colorectal cancer. Methods Data collection includes electronic databases, the National Center for Biotechnology Information, and Google Scholar, with several inclusion criteria: cell metabolism, glucose metabolism, nucleotide metabolism, and lipid metabolism in health and disease patients suffering from neurotoxicity, neuroinflammation, Parkinson’s disease, thymoma in myasthenia gravis. The initial number of collected and analyzed papers is 250. The final analysis included 150 studies out of 94 selected papers. After the selection process, 62.67% remains useful. Results and Conclusion A literature search shows that signaling molecules are involved in metabolic changes in cells. Differences between cancer and neuroimmunological diseases are present in the result section. Our finding enables insight into novel therapeutic targets and the development of scientific approaches for cancer and neurological disease onset, outcome, progression, and treatment, highlighting the importance of metabolic dysregulation. Current understanding, emerging research technologies and potential therapeutic interventions in metabolic programming is disucussed and highlighted.

show abstract

“…4c ), suggesting that LINC02283 may be a critical regulator in glioma biology. Lipid metabolism is reported to be significantly dysregulated in gliomas 44 . We evaluated scores of lipid metabolic pathways in OPC-like glial cells from different samples and found that these lipid metabolic pathways were enhanced in recurrent samples ( Fig.…”

Section: Resultsmentioning

confidence: 99%

An automated archival single-nucleus total RNA sequencing platform mapping integrative and retrospective cell atlas of gliomas

Xu,

Chen,

Lin

et al. 2023

Preprint

View full text Add to dashboard Cite

Single-cell RNA sequencing (scRNA-seq) has dramatically transformed biomedical research within laboratory settings. It has been extensively employed to investigate the heterogeneity and plasticity of glioma, the most prevalent brain tumor. However, the clinical diagnosis and treatment of glioma remain complex and challenging, highlighting the need for comprehensive cancer research. Currently available scRNA-seq platforms are insufficient to fulfill the demands posed by large-scale clinical applications. Here, we present an automated high-throughput single-nucleus total RNA sequencing platform, known as AAsnRandom-seq. This platform integrates automated single-nucleus isolation and droplet barcoding systems with the random primer-based scRNA-seq chemistry, designed to accommodate a diverse range of sample types. The performance and versatility of AAsnRandom-seq are validated using over one hundred clinical FFPE and frozen samples. AAsnRandom-seq was applied to archival FFPE samples of various glioma subtypes, including rare clinical samples, and matched primary-recurrent glioblastomas (GBMs), delving into the comprehensive molecular characteristic of glioma at single-cell level. Abundant non-coding RNAs (ncRNAs) with distinct expression profiles within different glioma clusters are detected. Promising recurrence-related targets and pathways are identified from the matched primary-recurrent GBMs. AAsnRandom-seq holds significant application value on large-scale integrative and retrospective clinical research using archived specimens.

show abstract

Lipid Alterations in Glioma: A Systematic Review

Cited by 12 publications

References 250 publications

Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment

Biogenic Amines Profile Characterization in Glioblastoma Patients Undergoing Standard of Care Treatment

Uncovering novel therapeutic targets in glucose, nucleotides and lipids metabolism during cancer and neurological diseases

An automated archival single-nucleus total RNA sequencing platform mapping integrative and retrospective cell atlas of gliomas

Contact Info

Product

Resources

About